Abstract:e16096 Background: Gastric cancer (GC) is the second cause of cancer-related death and metastasis is an important cause of death. Considering difficulties in searching for metastatic driver mutations, we tried a novel strategy to identify early drivers in primary gastric tumors. In this study, we conducted an integrative genomic analysis on GC patients and identified early drivers that lead to metastases. Methods: Tumors and matched normal tissues from 400 Chinese GC patients were characterized by whole-exome sequencing (WES), transcriptome sequencing and targeted exome sequencing (TES), especially the comparative analysis results between higher metastatic potential (HMP) group with T1 stage and lymph-node metastases, and lower metastatic potential (LMP) group without lymph-nodes or distant metastases. Functional experiments on candidate driver mutations were applied in GC cell lines to explore their roles in metastasis and immune escape. Results: HMP group presented higher mutation load and heterogeneity, enrichment in immunosuppressive signaling, lower tumor purity, more stromal and immune cell infiltration than LMP group. We identified 262 differentially expressed mRNA, lncRNA and miRNA between HMP and LMP group (with more than twice proportion of 2-fold increased or decreased tumor than normal tissue in HMP than LMP group, and with significantly 2-fold higher or lower in HMP tumors than LMP tumors). 168 candidate prometastatic mutations were found by WES and 8 were selected for following TES to detect their association with distant metastasis. We found that four candidate mutations were related to distant metastasis and mutated TP53 and MADCAM1 were significantly associated with poor metastasis-free survival. It’s worth noting that though with low mutational rate, MADCAM1 mutations were only observed in patients with metastasis within three years after surgery or at diagnosis. We demonstrated that MADCAM1-mutated proteins act as GOF mutants and could not only directly promote cancer cells migration, but also could trigger tumor metastasis by establishing complicated immunosuppressive microenvironment, including promoting PD-L1-mediated immune escape and reprogramming tumor-associated macrophages (TAMs). Conclusions: Our results showed that the GCs with different metastatic potential are distinguishable at the genetic level. A number of potential metastatic driver mutations was revealed in this study including known cancer-associated genes TP53. We also discovered some novel driver mutations, such as MADCAM1. The results indicate driver mutations in early-onset metastatic GC could promote metastasis not only by directly empower cancer cells to disseminate but also by establishing an immunosuppressive microenvironment. This study increased the understanding of molecular landscape of GC patients and provided possibility for future target therapy.

The emerging role of FAM46C as a biomarker and therapeutic target in gastric adenocarcinoma

VCAN – A novel prognostic marker for gastric cancer

Dissecting the Puzzling Roles of FAM46C: A Multifaceted Pan-Cancer Tumour Suppressor with Increasing Clinical Relevance

FAM196B Acts As Oncogene and Promotes Proliferation of Gastric Cancer Cells Through AKT Signaling Pathway

FAM46C is Critical for the Anti-Proliferation and Pro-Apoptotic Effects of Norcantharidin in Hepatocellular Carcinoma Cells

Comprehensive Analysis and Identification of Prognostic Biomarkers and Therapeutic Targets Among FAM83 Family Members for Gastric Cancer

Cmet As A Potential Therapeutic Target In Gastric Cancer

Characterization of the fatty acid metabolism gene signature in gastric cancer to assist precision treatment in chemotherapy

Fam198b as a novel biomarker for gastric cancer and a potential therapeutic target to prevent tumor cell proliferation dysregulation

Family with sequence similarity 153 member B as a potential prognostic biomarker of gastric cancer.

Upregulation of Family with Sequence Similarity 83 Member D Expression Enhances Cell Proliferation and Motility Via Activation of Wnt/β-catenin Signaling and Predicts Poor Prognosis in Gastric Cancer

Antimetastatic Effects of Norcantharidin on Hepatocellular Carcinoma Cells by Up-Regulating FAM46C Expression.

FAM64A aggravates proliferation, invasion, lipid droplet formation, and chemoresistance in gastric cancer: A biomarker for aggressiveness and a gene therapy target

<p>Upregulation of family with sequence similarity 83 member D expression enhances cell proliferation and motility via activation of Wnt/β-catenin signaling and predicts poor prognosis in gastric cancer</p>

A Genomic Signature Reflecting Fibroblast Infiltration Into Gastric Cancer Is Associated With Prognosis and Treatment Outcomes of Immune Checkpoint Inhibitors

FAM136A as a Diagnostic Biomarker in Esophageal Cancer: Insights into Immune Infiltration, m6A Modification, Alternative Splicing, Cuproptosis, and the ceRNA Network

IDDF2019-ABS-0245 Suppression of Fumarate Hydratase Activity Increases the Efficacy of Cisplatin-Mediated Chemotherapy in Gastric Cancer

Deep Targeted Sequencing And Its Potential Implication For Cancer Therapy In Chinese Patients With Gastric Adenocarcinoma

Identification and validation of Cystatin A as a novel promising therapeutic target for gastric cancer

Integrated DNA and RNA sequencing to reveal early drivers of metastasis in gastric cancer.

Novel Metabolic Biomarker for Early Detection and Diagnosis to the Patients with Gastric Cardia Adenocarcinoma